Log in

Kiniksa Pharmaceuticals (NASDAQ:KNSA) Downgraded by BidaskClub to Hold

Last updated on Friday, July 3rd, 2020 by MarketBeat

Kiniksa Pharmaceuticals (NASDAQ:KNSA) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating in a research note issued to investors on Friday, BidAskClub reports.

Other equities research analysts have also recently issued reports about the company. Goldman Sachs Group lifted their target price on Kiniksa Pharmaceuticals from $20.00 to $33.00 and gave the stock a "buy" rating in a research note on Tuesday. Zacks Investment Research cut Kiniksa Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research note on Wednesday. Wedbush lifted their target price on Kiniksa Pharmaceuticals from $30.00 to $38.00 in a research note on Monday. BofA Securities lifted their target price on Kiniksa Pharmaceuticals from $25.00 to $40.00 and gave the stock a "buy" rating in a research note on Monday. Finally, JPMorgan Chase & Co. lifted their target price on Kiniksa Pharmaceuticals from $22.00 to $24.00 and gave the stock an "overweight" rating in a research note on Wednesday, March 11th. Three investment analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. Kiniksa Pharmaceuticals has a consensus rating of "Buy" and an average target price of $31.14.

KNSA opened at $23.73 on Friday. The company has a market capitalization of $1.52 billion, a price-to-earnings ratio of -10.64 and a beta of 0.01. The firm's fifty day moving average price is $22.37 and its two-hundred day moving average price is $17.65. Kiniksa Pharmaceuticals has a 1 year low of $5.01 and a 1 year high of $28.67.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last posted its quarterly earnings data on Tuesday, April 28th. The company reported ($0.48) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.63) by $0.15. As a group, sell-side analysts forecast that Kiniksa Pharmaceuticals will post -2.31 EPS for the current fiscal year.

In related news, EVP Thomas W. Beetham sold 29,589 shares of the business's stock in a transaction dated Wednesday, July 1st. The stock was sold at an average price of $25.37, for a total value of $750,672.93. Following the sale, the executive vice president now directly owns 2,855 shares in the company, valued at approximately $72,431.35. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Thomas W. Beetham sold 13,752 shares of the business's stock in a transaction dated Wednesday, June 10th. The shares were sold at an average price of $25.07, for a total value of $344,762.64. Following the completion of the sale, the executive vice president now owns 43,341 shares in the company, valued at $1,086,558.87. The disclosure for this sale can be found here. Insiders sold a total of 90,764 shares of company stock worth $1,999,318 over the last 90 days. 70.63% of the stock is currently owned by company insiders.

Several institutional investors and hedge funds have recently made changes to their positions in the company. Foresite Capital Management IV LLC bought a new stake in shares of Kiniksa Pharmaceuticals during the first quarter valued at about $1,006,000. Vivo Capital LLC bought a new stake in shares of Kiniksa Pharmaceuticals during the first quarter valued at about $11,750,000. Two Sigma Investments LP increased its position in shares of Kiniksa Pharmaceuticals by 3.2% during the first quarter. Two Sigma Investments LP now owns 18,789 shares of the company's stock valued at $291,000 after buying an additional 578 shares during the period. Atom Investors LP bought a new stake in shares of Kiniksa Pharmaceuticals during the first quarter valued at about $2,991,000. Finally, Ikarian Capital LLC bought a new stake in shares of Kiniksa Pharmaceuticals during the first quarter valued at about $5,556,000. Hedge funds and other institutional investors own 31.79% of the company's stock.

Kiniksa Pharmaceuticals Company Profile

Kiniksa Pharmaceuticals, Ltd., a clinical-stage biopharmaceutical company, focuses on the discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need worldwide. Its clinical-stage product candidates include Rilonacept, which is in Phase II clinical trials for the treatment of recurrent pericarditis, an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody for the treatment of giant cell arteritis; and KPL-716, a monoclonal antibody, which is in Phase 1a/1b clinical trial for the treatment of prurigo nodularis and atopic dermatitis.

Featured Story: Understanding Compound Annual Growth Rate (CAGR)

Analyst Recommendations for Kiniksa Pharmaceuticals (NASDAQ:KNSA)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]

10 Buy and Hold Stocks to Add to Your Portfolio

“Set it and forget it” are words many investors don’t want to hear. Even the most venerable brokerage houses are encouraging their clients to actively trade so they can beat the market. Buy and hold is a relic, they say. It doesn’t reflect the reality of today.

In other words, “this time it’s different”.

As the ongoing volatility in the market shows you, it’s not different. It’s not even close to being different. The simple fact is that many active traders lose money by being too aggressive and too active for their own good.

And while it’s true that the market won’t always be this choppy, and certain stocks may be a great buy in months to come, right now investors are looking for safe harbors. One of the safest ways to invest is to find stocks that you can feel comfortable holding on to even in the worst of times. Frequently that can be because the stocks offer an attractive dividend. But sometimes, it’s also because they are in a market that is always in demand.

But that doesn’t mean you have to limit yourself to defensive stocks. You can find some quality buy-and-hold stocks that offer some attractive growth prospects.

View the "10 Buy and Hold Stocks to Add to Your Portfolio".

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.